These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24919870)

  • 1. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
    Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
    Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
    Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
    Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
    Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
    Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
    Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
    Jiménez-Varo E; Cañadas-Garre M; Gutiérrez-Pimentel MJ; Calleja-Hernández MA
    Pharmacogenet Genomics; 2014 Oct; 24(10):501-13. PubMed ID: 25089947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
    Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
    Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications.
    Sychev DV; Ignatyev IV; Emelyanov NV; Milovanova VV; Kossovskaya AV; Kukes IV; Tashenova AI; Kukes VG
    Bull Exp Biol Med; 2012 Oct; 153(6):886-8. PubMed ID: 23113310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
    Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
    Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
    Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
    Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N
    Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
    Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
    J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.